Bioventus Inc. (BVS) Misses Q2 EPS by 6c; Offers FY22 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
August 11, 2022 7:00 AM EDTDURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 2, 2022.
Q2 Financial Summary & Recent Highlights:
Net Sales of $140.3Â million, up $30.5Â million, or 27.8%, year-over-year as reported (28.6% constant currency*) and 8.1% organically* (8.8% constant currency*)Net Loss of ($8.0) million, compared to ($10.8)Â million in prior-year periodAdjusted EBITDA*Â of $22.9 million, compared to $19.9 million in prior-year periodLoss per share of Class A common stock of ($0.11), compared to... More